AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01369-07v1
52/5/1868    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kakeya, H.
Right arrow Articles by Kohno, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kakeya, H.
Right arrow Articles by Kohno, S.
Antimicrobial Agents and Chemotherapy, May 2008, p. 1868-1870, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01369-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis{triangledown}

Hiroshi Kakeya,1* Yoshitsugu Miyazaki,2 Hisato Senda,3 Tsutomu Kobayashi,1 Masafumi Seki,1 Koichi Izumikawa,1 Kazunori Yanagihara,1 Yoshihiro Yamamoto,1 Takayoshi Tashiro,1 and Shigeru Kohno1

Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan,1 Department of Bioactive Molecules, National Institute of Infectious Disease, Tokyo, Japan,2 Kaken Pharmaceutical Co., Ltd., Kyoto, Japan3

Received 24 October 2007/ Returned for modification 20 November 2007/ Accepted 16 February 2008

SPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

* Corresponding author. Mailing address: Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Phone: 81-95-819-7273. Fax: 81-95-849-7285. E-mail: kakeya{at}nagasaki-u.ac.jp

{triangledown} Published ahead of print on 25 February 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1868-1870, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01369-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.